Hepatitis C, Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Sclerotherapy for the Prevention of Variceal Bleeding in Cirrhosis: A Randomized Multicenter Trial | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search

Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Sclerotherapy for the Prevention of Variceal Bleeding in Cirrhosis: A Randomized Multicenter Trial

table  2.   Rebleeding
Total Sclerotherapy TIPS
Patients N° 81 43 38
Rebleeding
  Patients free of bleeding N° (%) 48 (59.3) 20 (46.5) 28 (73.7)
  Patients rebleeding N° (%) 31 (38.3) 22 (51.2) 9 (23.7)
  Lost to follow-up N° (%) 2 (2.4) 1 (2.3) 1 (2.6)
Total rebleeding episodes N° 53 41 12
Rebleeding site
  Esophageal varices N° (% of bleeds) 35 (66.0) 28 (68.3) 7 (58.3)
  Esophageal ulcer N° (% of bleeds) 5 (9.4) 5 (12.2) 0
  PHG N° (% of bleeds) 2 (3.8) 2 (4.9) 0
  Other N° (% of bleeds) 6 (11.3) 3 (7.3) 3 (25.0)
  Unknown N° (% of bleeds) 5 (9.5) 3 (7.3) 2 (16.7)


Return To Article

Table Of Contents


Download our Free Reports Download our Free Reports
Thank You!

You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.

If you still haven't received our email after a few minutes, please feel free to contact us.

Close Window